Capricor Therapeutics, Inc. (CAPR, Financial) saw a notable stock increase of 5.04%, reaching $19.97 per share. The trading volume was approximately 991,132 shares, with a turnover rate of 2.18% and a price fluctuation of 7.47%. Recent financial results showed revenue of $2.26 million and a net loss of $12.56 million, equating to an earnings per share of -$0.38. The company's gross profit was $1.90 million, with a price-to-earnings ratio of -19.55.
All seven analysts covering the stock have given it a "buy" rating, with no "hold" or "sell" recommendations. The biotechnology sector, where Capricor operates, experienced a modest increase of 0.05%. Notable stocks in the industry with significant activity include Senti Biosciences, Inc., Purple Biotech Ltd, and Quoin Pharmaceuticals Ltd.
Capricor Therapeutics focuses on cell and exosome therapies for rare diseases, with products like CAP-1002 in clinical trials for Duchenne muscular dystrophy.
